Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFeedback Regulatory News (FDBK)

Share Price Information for Feedback (FDBK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 82.50
Bid: 80.00
Ask: 85.00
Change: 0.00 (0.00%)
Spread: 5.00 (6.25%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 82.50
FDBK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Bleepa - revolutionising clinical messaging

26 Jul 2019 12:03

RNS Number : 8929G
Feedback PLC
26 July 2019
 

 

Feedback plc

 

BleepaTM - revolutionising clinical messaging

 

New medical grade imaging app to be launched at NHS Expo on 4-5 September 2019

 

Cambridge, 26 July 2019: Further to the Company's strategic review announcement on 10 July 2019, Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist medical imaging technology company, today provides an update on its new clinical messaging product: BleepaTM.

 

As previously announced, Feedback plans to establish a leading role in the medical communication market. BleepaTM, its new app for clinicians, is currently in beta development and will be formally launched at NHS Expo on 4-5 September 2019 in Manchester.

 

Based on Feedback's Cadran technology, BleepaTM is a secure, encrypted medical communication tool accessible through smartphones, tablets and desktops that facilitates rapid clinical messaging and review of medical grade imaging for all members of a clinical team, directly from a hospital Picture Archiving and Communications System (PACS). BleepaTM enables faster clinical decision making between team members wherever they are, accelerating and improving patient care.

 

According to an article published in BMJ Innovations, 97% of hospital doctors routinely use WhatsApp to communicate about patients.1

 

This increasing trend for clinicians to use personal devices to discuss patient care and make clinical decisions is more convenient and efficient than traditional methods of clinical communication. However, using such methods opens doctors and their patients up to a variety of risks.

 

BleepaTM addresses growing concerns about these messaging platforms not meeting diagnostics clinical standards and regarding patient data protection. Continued use of non-specialist communication tools could leave both hospitals and individual clinical users significantly exposed and therefore open to the risk of litigation.

 

The Directors believe BleepaTM will be the only communication tool to be a CE marked medical device. More information can be found at www.bleepa.com.

 

Dr Tom Oakley, CEO of Feedback, commented:

 

"We are making rapid progress in the development of our new messaging app, BleepaTM. We believe that it will provide a flexible, accurate and secure method for swift clinical decision making, revolutionising the way in which patients receive treatment whilst safeguarding our doctors from potential litigation. We look forward to showcasing the finished product this September at NHS Expo in Manchester."

 

1 O'Sullivan DM, O'Sullivan E, O'Connor M, et al WhatsApp Doc? BMJ Innovations 2017;3:238-239.

 

-Ends-

Enquiries:

 

Feedback plc

+44 (0)1954 718072

Tom Oakley, CEO

IR@fbk.com

Lindsay Melvin, CFO

 

Instinctif Partners

+44 207 457 2020

Rozi Morris/Phillip Marriage

Feedbackplc@instinctif.com

 

Notes to editors About Feedback plc

Feedback plc (AIM: FDBK) is a specialist medical imaging technology company providing innovative software and systems, through its fully-owned trading subsidiary, Feedback Medical Limited. Its products advance the work of radiologists, clinicians and medical researchers by improving workflows and giving unique insights into diseases, particularly cancer. Feedback Medical works with customers globally from headquarters in the internationally renowned scientific hub of Cambridge, UK. Its proprietary technologies are TexRAD®, the quantitative texture analysis tool and Cadran, a picture archiving communication system (PACS). For more information, see www.fbk.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRAFQLFLKDFBBBF
Date   Source Headline
2nd Nov 20217:00 amRNSFinal Results
19th Oct 20217:00 amRNSPilot Scheme with Sussex Integrated Care System
11th Oct 20217:00 amRNSMOU with Quest Teleradiology
29th Sep 20217:00 amRNSFeedback Joins NHS AI Procurement Framework
23rd Sep 20217:00 amRNSOfficial Launch of Bleepa Box
14th Sep 20217:00 amRNSMemorandum of Understanding with Qure.ai
9th Sep 20217:00 amRNSLaunch of CareLocker to enhance Bleepa technology
25th Aug 20217:00 amRNSChange of Adviser
3rd Aug 20217:00 amRNSDigital Health article highlights Bleepa potential
16th Jul 20217:00 amRNSBleepa agreement with CVS Equine Division
5th Jul 202110:17 amRNSHolding(s) in Company
30th Jun 20213:30 pmRNSBoard Update
29th Jun 20217:00 amRNSUK Medical Device Certification for Bleepa
10th Jun 20217:00 amRNSBleepa available on Apple App Store & Google Play
8th Jun 20217:00 amRNSYear End Trading Update
6th May 20217:00 amRNSExecutive Appointment
24th Mar 20217:00 amRNSRoyal Berkshire NHS Foundation Trust Contract
23rd Feb 20217:00 amRNSHalf-year Report
19th Jan 20217:00 amRNSBleepa builds on robust data management security
4th Dec 20207:00 amRNSBleepa to join DIT’s first virtual event to India
10th Nov 20209:06 amRNSSelected for Digitalhealth.London 2020 Programme
6th Nov 20203:03 pmRNSResult of Annual General Meeting - Amendment
6th Nov 20201:50 pmRNSHolding(s) in Company
5th Nov 20201:23 pmRNSResult of AGM
5th Nov 20207:01 amRNSBleepa selected for WISH 2020 Innovation Awards
5th Nov 20207:00 amRNSAGM Statement
28th Oct 20203:10 pmRNSDirector/PDMR Shareholding
20th Oct 20207:00 amRNSBleepa adds 3D Imaging with Axial3D Partnership
13th Oct 20207:00 amRNSFinal Results
26th Aug 20201:34 pmRNSHolding(s) in Company
7th Aug 20207:00 amRNSDirector/PDMR Shareholding
5th Aug 20204:36 pmRNSPrice Monitoring Extension
31st Jul 20205:00 pmRNSTotal Voting Rights
30th Jul 20203:48 pmRNSBleepa appointed to major NHSx framework
29th Jul 20202:06 pmRNSSecond Price Monitoring Extn
29th Jul 20202:00 pmRNSPrice Monitoring Extension
15th Jul 20207:00 amRNSAppointment of Non-Executive Director
10th Jul 20207:00 amRNSHolding(s) in Company
7th Jul 20207:00 amRNSHolding(s) in Company
6th Jul 202011:01 amRNSHolding(s) in Company
6th Jul 202010:36 amRNSHolding(s) in Company
6th Jul 20207:00 amRNSHolding(s) in Company
6th Jul 20207:00 amRNSHolding(s) in Company
1st Jul 202012:46 pmRNSResult of Open Offer and General Meeting
25th Jun 202011:59 amRNSDirector/PDMR Shareholding
15th Jun 20207:00 amRNSPlacing, Open Offer and Notice of GM
1st Jun 20207:00 amRNSBleepa® achieves CE Mark
21st May 20207:00 amRNSPapworth NHS Hosp - contract renewal with Bleepa
29th Apr 20202:05 pmRNSSecond Price Monitoring Extn
29th Apr 20202:00 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.